|
Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer Clinical research trials and Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer. Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer  Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer
Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer
For Condition: stage 4 non-small cell lung cancer,stage 3B non-small cell lung cancer,recurrent non-small cell lung cancer,stage 3A non-small cell lung cancer
Status: No longer recruiting
Sponsor(s): EORTC Lung Cancer Cooperative Group ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have advanced non-small cell lung cancer that cannot be treated with surgery.
Details: OBJECTIVES: I. Determine the effect of acridine carboxamide on objective response, response rate, and duration of response in patients with unresectable, locally advanced, progressive or metastatic non-small cell lung cancer. II. Determine the toxicities and pharmacokinetics of this regimen in these patients. PROTOCOL OUTLINE: This is a multicenter study. Patients receive acridine carboxamide IV over 24 hours for 5 days. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks until disease progression or commencement of another treatment. PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven unresectable, locally advanced, progressive or metastatic non-small cell lung cancer; Not amenable to curative surgery or radiotherapy; No prior first line chemotherapy for metastatic or advanced disease - At least 1 bidimensionally measurable target lesion by CT scan - No symptomatic brain metastases --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: See Disease Characteristics; No prior chemotherapy - Endocrine therapy: Not specified - Radiotherapy: At least 4 weeks since prior radiotherapy - Surgery: At least 2 weeks since prior major surgery - Other: No other concurrent anticancer agents; No other concurrent investigational therapy --Patient Characteristics-- - Age: 18 and over - Performance status: ECOG 0-2 - Life expectancy: At least 3 months - Hematopoietic: WBC greater than 3,000/mm3; Platelet count greater than 100,000/mm3 - Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN); SGOT, SGPT, and alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver metastases present) - Renal: Creatinine no greater than 1.7 mg/dL - Cardiovascular: No ischemic heart disease within the past 6 months; Normal 12 lead ECG - Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; No other prior or concurrent malignancy except cone biopsied carcinoma of the cervix or adequately treated basal or squamous cell skin cancer; No unstable systemic disease or active uncontrolled infection; No psychological, familial, sociological, or geographical condition that could preclude compliance
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AxelHanauske, Study Chair, EORTC Lung Cancer Cooperative Group
Rigshospitalet
Copenhagen, , 2100
Denmark
CHU de la Timone
Marseille, , 13385
France
Hospital Universitario 12 de Octubre
Madrid, , 28041
Spain
Kaiser Franz Josef Hospital
Vienna, , A-1100
Austria
Haemato-Onkologische Praxis und Tagesklinik
Munich, , D-80639
Germany
Centre de Lute Contre le Cancer,Georges-Francois Leclerc
Dijon, , 21079
France
Istituto Nazionale per lo Studio e la Cura dei Tumori
Naples, , 80131
Italy
Istituti Fisioterapici Ospitalieri - Roma
Rome, , 00161
Italy
Additional Information:
Study ID Numbers: CDR0000067384; EORTC-16991N
Study Start Date: September 1999
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004151
Other Recurrent Non-Small Cell Lung Cancer Studies:
1. Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Unresectable Brain Metastases From Non-Small Cell Lung Cancer
2. Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
3. Phase II Study of TLK286 in Patients With Advanced Non-Small Cell Lung Cancer
4. Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
5. Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Related Studies:
Other recurrent non-small cell lung cancer Clinical Trials
Other Clinical Trials
Other Dijon Clinical Trials
Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer
|
|
|
|
|
|
|
|
